OncoSec Medical FCF per Share
Delisted
Free Cash Flow per Share of OncoSec Medical (ONCS) as of Aug 11, 2026.
Get this data via API
Financial Data API
FCF per Share
0.00USD
Last updated:
Free Cash Flow per Share of OncoSec Medical is 2026 0.00 USD. Free Cash Flow per Share of OncoSec Medical was 2025 0.00 USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
OncoSec Medical Stock analysis
What does OncoSec Medical do? OncoSec Medical Inc is a US-based company specializing in the development of cancer treatment methods through immunotherapy. The company was founded in 2011 and is headquartered in San Diego, California.
The history of OncoSec Medical Inc began with the idea of improving tumor treatments through electroporation. Electroporation is a process that uses electric pulses to increase the permeability of cell membranes. This facilitates the exchange of molecules and the uptake of drugs, which is used in the treatment of cancer cells.
The business model of OncoSec Medical Inc is based on the development and commercialization of immunotherapies to combat cancer. Electroporation is used to locally infect tumor lesions with reactivated T-cells and other immune cells to generate an immune response. OncoSec Medical Inc has developed a proprietary platform called ImmunoPulse, which combines electroporation and immunotherapy.
The company is divided into various divisions, including research and development, clinical trials, manufacturing, and distribution. Research and development focus on identifying potential immunotherapies and testing drug candidates. Clinical trials are designed to confirm the effectiveness and safety of therapies through clinical testing. Manufacturing involves the production of drug candidates and clinical preparations in accordance with Good Manufacturing Practices (GMPs). Distribution includes the sale and marketing of approved therapies to patients and healthcare providers.
OncoSec Medical Inc offers a variety of immunotherapies for the treatment of various types of cancer. This includes ImmunoPulse IL-12 therapy, which is used to treat metastatic melanoma. The company is also working on several other therapies, including the Verapamil-Plus-IL-2 protocol for the treatment of breast and prostate cancer.
In summary, OncoSec Medical Inc is an emerging biotechnology company specializing in the development and commercialization of immunotherapies to combat cancer. Through its proprietary ImmunoPulse platform and extensive research and development, the company strives to provide effective and safe treatment options for cancer patients, fully harnessing the potential of immunotherapy. OncoSec Medical is one of the most popular companies on Eulerpool.
Frequently Asked Questions about OncoSec Medical stock
On Eulerpool you can find the complete historical development of Free Cash Flow per Share OncoSec Medical since 2006 – with annual values, charts, and detailed analysis.
FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.
Access this data via the Eulerpool API
Cash Flow — OncoSec Medical
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — OncoSec Medical
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth